or Try an Advanced Search...

    Technical Analysis for AKRO - Akero Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 20.22 1.66% 0.33
    AKRO closed up 1.38 percent on Tuesday, April 30, 2024, on 53 percent of normal volume.
    Earnings due: May 13
    *** please verify all earnings dates ***
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Flat
    Historical AKRO trend table...
    Date Alert Name Type % Chg
    1,2,3 Retracement Bearish Bearish Swing Setup 1.66%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.66%
    Multiple of Ten Bearish Other 1.66%
    Gapped Up Strength 1.66%
    Multiple of Ten Bearish Other 3.06%
    Oversold Stochastic Weakness 3.06%
    Jack-in-the-Box Bearish Bearish Swing Setup 2.43%
    Lower Bollinger Band Walk Weakness 2.43%
    Inside Day Range Contraction 2.43%
    Lower Bollinger Band Touch Weakness 2.43%
    Older End-of-Day Signals for AKRO ...

       Recent Intraday Alerts

    Alert Time
    60 Minute Opening Range Breakdown about 4 hours ago
    10 DMA Resistance about 5 hours ago
    Rose Above Previous Day's High about 5 hours ago
    Rose Above 10 DMA about 5 hours ago
    Up 3% about 5 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AKRO Chart by TradingView
    Basic chart:

    Profile

    Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases with high unmet medical need. The company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biotechnology Alcohol Clinical Trial Hepatitis Steatohepatitis Metabolic Disease Non Alcoholic Fatty Liver Disease

    Is AKRO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 30 Akero Therapeutics names Scott Gangloff as CTO
    Apr 30 Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer
    Apr 3 Akero Therapeutics' EFX Data Warrants Caution
    Mar 20 Billionaire Steve Cohen and Insiders Are Buying These 10 Stocks
    Mar 18 Ozempic Can’t Do It All—A Potential New Blockbuster Is a Reminder of That
    Mar 15 Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
    Mar 14 Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
    Mar 8 Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
    Mar 7 Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
    Mar 7 President and CEO Andrew Cheng Sells 75,000 Shares of Akero Therapeutics Inc (AKRO)
    See more AKRO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 58.38
    52 Week Low 11.25
    Average Volume 1,402,868
    200-Day Moving Average 28.57
    50-Day Moving Average 24.52
    20-Day Moving Average 21.44
    10-Day Moving Average 20.31
    Average True Range 1.24
    RSI (14) 35.48
    ADX 32.87
    +DI 11.35
    -DI 31.25
    Chandelier Exit (Long, 3 ATRs) 21.56
    Chandelier Exit (Short, 3 ATRs) 21.93
    Upper Bollinger Bands 24.12
    Lower Bollinger Band 18.75
    Percent B (%b) 0.21
    BandWidth 25.06
    MACD Line -1.31
    MACD Signal Line -1.22
    MACD Histogram -0.0861
    Fundamentals Value
    Market Cap 1.11 Billion
    Num Shares 55.7 Million
    EPS -2.29
    Price-to-Earnings (P/E) Ratio -8.69
    Price-to-Sales 0.00
    Price-to-Book 1.89
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 21.39
    Resistance 3 (R3) 21.37 20.85 21.14
    Resistance 2 (R2) 20.85 20.47 20.86 21.06
    Resistance 1 (R1) 20.37 20.23 20.11 20.39 20.97
    Pivot Point 19.85 19.85 19.72 19.86 19.85
    Support 1 (S1) 19.37 19.47 19.11 19.39 18.81
    Support 2 (S2) 18.85 19.23 18.86 18.72
    Support 3 (S3) 18.37 18.85 18.64
    Support 4 (S4) 18.39